Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

NCT ID: NCT03769129

Last Updated: 2024-06-25

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-11-01
• Study Completion Date: 2029-11-01

Brief Summary

This is a prospective, randomized, single clinical study designed to evaluate its safety and efficacy by using Microwave Ablation combine with Pembrolizumab in patients with Stage ⅢB-Ⅳ Non-small Cell Lung.Cancer (NSCLC) who failed with first-line therapy.

Detailed Description

Lung cancer is one of the most common malignant tumors in the world and has become the No. 1 cause of death from malignant tumors in China. Non-small cell lung cancer (NSCLC) includes squamous cell carcinomas, adenocarcinomas, and large cell carcinomas and accounts for about 80-85% of all lung cancers. NSCLC cancer cells divide slowly in a diffusive manner and metastasize at a relatively late stage compared to small cell carcinomas. A majority of patients with NSCLC are already in advanced stages and have a low 5-year survival rate.

Treatments for advanced NSCLC include chemotherapy ,targeted therapies and immunotherapy. The microwave ablation is the good choice for patients who cannot tolerate surgical resection. A large number of studies have shown that local minimally invasive ablation therapy within a certain temperature range can stimulate the body to produce an immune response to varying degrees. The study found that for a variety of malignant tumor models, thermal ablation local treatment of in situ tumors, while the disappearance of other metastatic lesions, and treated mice are resistant to secondary vaccination of the same tumor, proving that thermal ablation therapy stimulates long-lasting Anti-tumor immunity. Pembrolizumab are representative drugs for immunosuppressive agents, and its indications have been approved in various types of tumors, including advanced melanoma, advanced squamous non-small cell lung cancer, advanced renal cell carcinoma, and classical Hodgkin's lymphoma and late recurrent head and neck squamous cell carcinoma patients. Whether the combination of the two can cause a stronger anti-tumor immune response in the body. However, the flexibility, safety and efficacy of using Microwave Ablation combine with Pembrolizumab in NSCLC patients are still unclear.

Conditions

Non Small Cell Lung Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Microwave ablation

Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.

Group Type: EXPERIMENTAL

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab

microwave ablation

Intervention Type: PROCEDURE

microwave ablation

Pembrolizumab

Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.

Group Type: OTHER

Pembrolizumab

Intervention Type: DRUG

Pembrolizumab

microwave ablation

Intervention Type: PROCEDURE

microwave ablation

Interventions

Pembrolizumab

Pembrolizumab

Intervention Type: DRUG

microwave ablation

microwave ablation

Intervention Type: PROCEDURE

Other Intervention Names

Keytruda

Eligibility Criteria

Inclusion Criteria

1. Pathologically diagnosed IIIB or IV non-small cell lung cancer.

2. Previously accepted first-line standard treatment failure or recurrence

3. At least one measurable lesion.

4. The patient has not received any other anti-cancer treatment within four weeks.

5. Any gender, age ≥18 years

6. ECOG PS : 0-2 points

7. Expected survival ≥ 6 months

8. The level of organ function meets the following criteria.

(1) subject to the standard blood test: ANC ≥ 1.5×109 / L, PLT ≥ 50×109 / L, Hb ≥ 90g/L.

(2) biochemical tests must meet the following criteria: TBIL<1.5×ULN, ALT, AST <2.5×ULN ( if liver metastasis ALT, AST can be <5×ULN), BUN, and Cr ≤ 1×ULN).

9. Female patients in child bearing period must have evidence of negative pregnancy test, and agree to take effective contraceptive measures until 6months after therapy.

10. Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.

Exclusion Criteria

1. Patients with two or more kinds of tumors.

2. Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.

3. Patients with seropositive response of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.

4. Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.

5. Patients with severe heart and lung dysfunction.

6. Patients with severe chronic diseases of kidney, liver and other important organs.

7. Patients with any other serious illness that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on.

8. Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment.

9. Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.

10. Patients who need long-term use of glucocorticoid.

11. Women patients in gestation period or suckling period.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Second Affiliated Hospital of Guangzhou Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

zhang zhenfeng, MD,PHD

Role: PRINCIPAL_INVESTIGATOR

Second Affiliated Hospital of Guangzhou Medical University

Locations

zhang Zhenfeng

Guangzhou, Guangdong, China

Site Status: RECRUITING

Countries

China

Central Contacts

zhang zhenfeng, MD,PHD

Role: CONTACT

zhangzhf@gzhmu.edu.cn

02034153532

CHEN deji, MD,PHD

Role: CONTACT

chendeji2003@163.com

02034153532

Facility Contacts

Zhang Zhenfeng

Role: primary

zhangzhf@gzhmu.edu.cn

13202005598

Other Identifiers

ZZWMAICI-005

Identifier Type: -

Identifier Source: org_study_id